Novo Nordisk (NVO) Stock Outlook Positive with Focus on Diabetes and Obesity Drugs

Novo Nordisk A/S (NYSE:NVO) ranks among the best medical stocks to buy according to analysts. On July 18, Deutsche Bank reaffirmed its Buy rating for Novo Nordisk A/S (NYSE:NVO), citing a price target of DKK750. The firm continues to have a favorable outlook on the Danish pharmaceutical company ahead of its upcoming second-quarter earnings report.

In a July 8 preview headlined “EU Pharma: Q2 preview: things have got a little slipperier; may present opportunities,” Deutsche Bank analyst Emmanuel Papadakis offered his impressions of Novo Nordisk’s Q2. The bank accepts the potential for a trim at the upper end of Novo Nordisk’s projection, although it thinks a guiding range revision is unlikely.

Novo Nordisk A/S (NYSE:NVO) is a prominent global healthcare company that focuses on treating rare diseases, diabetes, and obesity. With 48,000 workers spread across more than 168 countries, Novo Nordisk is well-known for its pharmaceuticals, which include Wegovy, Rybelsus, and Ozempic.

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.